Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Sznol Discusses Immunotherapy Combinations in RCC

June 1st 2018

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses immunotherapy combinations in renal cell carcinoma.

Urology Practice Keeps Up With Technology Through Physician-Owned Business Model

June 1st 2018

Greater Boston Urology strives to offer comprehensive urologic care that includes up-and-coming diagnostics and treatments, such as the Prostate Health Index blood test and high intensity–focused ultrasound.

Dr. O'Neil on Adjuvant Therapy in Bladder Cancer

June 1st 2018

Brock O’Neil, MD, assistant professor, Division of Urology, University of Utah School of Medicine, Huntsman Cancer Institute, discusses adjuvant therapy for patients with bladder cancer.

Nanus Discusses Importance of Neoadjuvant and Adjuvant Care in RCC

May 30th 2018

David M. Nanus, MD, discusses the promise of immunotherapy and the continued role of surgery in the treatment in renal cell carcinoma.

Dr. Agarwal Discusses Recent FDA Approvals in RCC

May 30th 2018

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses recent FDA approvals in renal cell carcinoma.

ASCO 2018: Top Oncologists Select Key, Practice-Changing Abstracts

May 30th 2018

Key opinion leaders spoke with OncLive ahead of the 2018 ASCO Annual Meeting to share the top abstracts they believe could have the greatest impact on clinical practice and patient outcomes across lymphomas, gastrointestinal cancers, genitourinary cancers, and lung cancer.

Dr. McGregor on New Combinations With Immunotherapy in RCC

May 23rd 2018

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses new combinations with immunotherapy in renal cell carcinoma.

Dr. Sznol Discusses the Importance of Clinical Trials in RCC

May 22nd 2018

Mario Sznol, MD, professor of Medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the importance of clinical trials in renal cell carcinoma.

FDA Warns Against Single-Agent Checkpoint Inhibition for PD-L1-Low Untreated Urothelial Carcinoma

May 19th 2018

The FDA has issued a drug safety notification warning against the use of frontline single-agent immune checkpoint inhibition for patients with PD-L1–low expressing platinum-eligible urothelial carcinoma.

Dr. Harshman on Earlier Use of Immunotherapy in RCC

May 18th 2018

Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses moving immunotherapy earlier in the line of therapy for patients with renal cell carcinoma (RCC).

Frontline Cabozantinib Approved in Europe for Advanced RCC

May 18th 2018

The European Commission has approved cabozantinib (Cabometyx) for previously untreated patients with intermediate- or poor-risk advanced renal cell carcinoma.

Dr. Choueiri Discusses the Current State of RCC Treatment

May 17th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the current treatment of patients with renal cell carcinoma.

Motzer Helps Set the Pace of Discovery in Kidney Cancer Research

May 17th 2018

Robert J. Motzer, MD, has been at the forefront of research into renal cell carcinoma for nearly 30 years, with his work contributing to the approval of at least 8 new drugs.

Biomarker Dilemma Persists With Immunotherapy in Bladder Cancer

May 15th 2018

The quest continues to identify a predictive biomarker of response to more precisely treat patients with checkpoint inhibitors that, while markedly beneficial to some patients, are not without their own costs and associated immune-related adverse effects.

Harshman Addresses Potentially Practice-Changing Adjuvant Therapy Trials in RCC

May 14th 2018

Lauren C. Harshman, MD, discusses ongoing clinical trials examining the incorporation of immune therapies into practice.

Focusing on Risk Stratification in Prostate Cancer

May 14th 2018

The National Comprehensive Cancer Network has overhauled its guidelines for managing prostate cancer with a greater emphasis on risk stratification for molecular testing and therapy choices.

Standard of Care Continues to Shift in RCC

May 11th 2018

Toni K. Choueiri, MD, discusses recent advancements and shares his insight on the future treatment landscape of patients with kidney cancer.

Dr. Balar on Impact of Durvalumab Plus Tremelimumab in Bladder Cancer

May 10th 2018

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the impact of the combination of durvalumab (Imfinzi) plus tremelimumab in metastatic bladder cancer.

Dr. Harshman Discusses the Potential for New RCC Treatments

May 10th 2018

Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses the potential for new treatment options in renal cell carcinoma.

Expert Underscores Importance of AE Management in GU Cancers

May 10th 2018

Xiao X. Wei, MD, MAS, discusses managing possible adverse events of different systemic therapies in kidney and bladder cancer.